House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Rheumatology

Rheumatoid arthritis: disease-modifying treatment — 2025 update

EULAR · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

EULAR’s official account of its rheumatoid arthritis update describes the main treatment principles and selected changes in DMARD strategy. It provides a focused view of the update rather than the full recommendation set.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Base treatment on specialist assessment and shared decisions

  • Rheumatologists should provide the principal specialist care for people with rheumatoid arthritis. [1]
  • Make decisions jointly with the patient, taking account of disease activity, safety, comorbidities and structural-damage progression. Recognize that several successive therapies with different mechanisms may be needed over a patient’s lifetime. [1]
  • Start DMARD treatment as soon as rheumatoid arthritis is diagnosed. [1]

Interpret the stated strategy changes

  • After the initial treatment strategy fails, the update removes further stratification by poor-outcome risk factors: failure of that strategy is itself considered such a risk factor. This statement does not specify the next drug or its dose. [1]
  • Once glucocorticoids have been stopped and sustained remission is present, the revised wording prefers continuing DMARDs. Dose reduction may still be considered; this is not a recommendation to stop DMARD treatment altogether. [1]
  • The update does not add a pre-rheumatoid-arthritis treatment recommendation, because the developing evidence in this field was not considered mature enough to support one. [1]

Limitations and use

  • The reviewed source is the official EULAR release describing selected recommendations. It does not provide the complete recommendation set, drug doses, monitoring intervals, detailed treatment targets or complete safety qualifications for individual DMARD classes. Do not infer those missing details from this summary.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Rheumatoid arthritis: disease-modifying treatment — 2025 update — focused recommendation source

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
EULAR
First published
12 March 2026
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: rheumatoid arthritis eular

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Base treatment on specialist assessment and shared decisions
  • Interpret the stated strategy changes
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House